Burden of Paediatric Rotavirus Gastroenteritis & Potential Impact of Rotavirus Vaccination
|
|
- Wendy Dixon
- 6 years ago
- Views:
Transcription
1 Carlo GIAQUINTO Pediatrics Department University of Padova, Italy Burden of Paediatric Rotavirus Gastroenteritis & Potential Impact of Rotavirus Vaccination Preliminary results 7th International Rotavirus Symposium Lisbon, June 2006
2 REVEAL Study Design Rotavirus gastroenteritis Epidemiology and Viral types in Europe Accounting for Losses in Public Health & Society Prospective multicentre observational study 7 European regions from Oct 1, 2004 Sept 30, 2005 Study population: - Children <5 years of age with AGE - living in the defined study area Sweden 3 Settings - all Hospitals in study area (n total =12) - all Emergency Dept. in study area (n total =16) - GPs and/or Peadiatricians (n total =139) U.K. Belgium Germany France Selected Study objectives: -Annual rate of consultation due to AGE at hospitals, emergency rooms, GP, FP or Paediatricians -Costs of RV disease Spain Italy 2
3 Objectives To assess the burden of RVGE* and the impact of Rotavirus vaccination from 2 perspectives: the health care payer (direct costs) the society (direct + indirect costs). Means:By amodel comparing 2 cohorts up to age 5. No rotavirus vaccination Universal rotavirus vaccination program in infants Outcomes Costs of RVGE* Outcomes Residual costs of RVGE* * RVGE = Rotavirus gastroenteritis 3
4 Overview of the Model : Decision Tree Subtree No rotavirus or no symptomatic RVGE Hospital acquired RVGE (No Payoff) Birth cohort No RV Vaccination programme Community-acquired RVGE RVGE seeking care No medical attendance for RVGE GP pattern pgp Emergency pattern per Hospitalisation pattern phosp Phone call No phone call (No Payoff (No Payoff (No Payoff (No Payoff (No Payoff RV vaccination programme Vaccinated No vaccinated [+] [+] Subtree Subtree Model: Performed on Excel software. Adapted from the US model of Tucker et al. (JAMA 1998). Takes into account rotavirus nosocomial infections and «phone consultations». 4
5 Which Data Do We Use in the Model? REVEAL Epidemiological and Cost Study Incidence of FP visits for RVGE Incidence of emergency visits for RVGE Incidence of hospitalisations for RVGE Health care resource utilisation (number of consultations, medicines ) Unit Cost data National Official sources Literature / Expert assumptions % of rotavirus not seeking care Distribution of serotypes Incidence of nosocomial infections REST (Rotavirus Efficacy and Safety Trial) with pentavalent Rotavirus vaccine Reduction in hospitalisations, emergency visits, physician visits 5
6 Model Inputs Pentavalent Rotavirus Vaccine Efficacy / Effectiveness Efficacy data based on REST clinical study publication (Vesikari et al. NEJM 2006) and experts assumptions. 3 scenarios for efficacy: Base Minimum Highest Focus on the base- case scenario of efficacy GP cases Emergency cases Hospitalisations Nosocomial infections Deaths Cases not seeking care Efficacy for children receiving at least 1 dose Waning rate Coverage rate Effectiveness to reduce % * [95%CI: 73.9% %] ** % * [95%CI: 88.8% %] ** % * [95%CI: 90.5% %] ** % * [95%CI: 90.5% %] ** % * [95%CI: 90.5% %] ** % * [95%CI: 73.9% %] ** 60 % * 10 % after 2 years * 90 % * [70 % - 80 %] ** * Base-case efficacy ** [Minimum efficacy, Highest efficacy] 6
7 Incidence rate of AGE and RVGE per 1000 children per year in each area stratified by setting Incidence rate dependent on country Health System # children Emergency room AGE RVGE # children GP/FP AGE RVGE country Belgium France Germany Italy Spain Sweden UK Belgium France Germany Italy Spain Sweden country UK # children Hospital AGE RVGE 10 5 REVEAL study 0 country Belgium France Germany Italy Spain Sweden UK
8 Main Epidemiological Inputs based on REVEAL Study - Italy RVGE Incidences Value Incidence of hospitalised cases* 5.3/1000 Incidence of emergency cases* 18.9/1000 Incidence of cases seen by physicians* 22.7/1000 * In children < 5 years 8
9 Main Epidemiological Inputs - Italy Value Source / Justification Birth cohort 531,000 UNICEF statistics (year 2003) Incidence of nosocomial infections* 1.6/1000 Assumption based on Gleizes et al. PIDJ (2006): For 1 community-acquired RV, 0.6 Rotavirus nosocomial infection % of cases not seeking medical attention 42.3 % Itzler et al. PAS Annual Meeting (2005) Number of deaths / year* 10 Soriano-Gabarro et al. PIDJ (2006) * In children < 5 years 9
10 Main Economic Inputs based on Reveal Cost study - Italy REVEAL Cost Study Cost of RVGE cases used in the model Items FP* office visit Unit costs 18.5 Perspective Payer Society Nurse home visit Emergency room visit FP case Assessment Ward Hospitalisation stay Stool test (viral) Emergency case Work day lost Baby-sitter 8.5 /h Hospitalised case Healthcare resources utilised during REVEAL multiplied by Italian unit costs enable an estimation of a mean cost per RVGE case. 10 * Family Paediatrician
11 Main Economic Inputs - Italy Payer Society Nosocomial infections* Cases treated at home** 0 39 * Gianino et al. JHI (2002), Soriano et al. PIDJ (2006) ** OECD Indicators, Eurostat (2002) 11
12 Need to target a high coverage rate to ensure optimal reduction of RVGE burden 0% 90 % Coverage rate 80 % Coverage rate 70 % Coverage rate -20% Reduction in RVGE Burden -40% -60% -80% -80% -75% -70% -71% -67% -59% -62% -59% -52% -100% Highest case efficacy Base-case efficacy Minimum case efficacy 12
13 Impact of the Pentavalent Rotavirus Vaccine on the RVGE Burden in Italy 10 Deaths Without vaccination Nosocomial Infections Hospitalisations Emergency Visits Physician Visits Not seeking care - 75% With rotavirus vaccination Base-case efficacy children Coverage rate = 90% 2 Deaths Nosocomial Hospitalisations Emergency Physician Not seek 13
14 Impact of the Pentavalent Rotavirus Vaccine to Reduce Cost of Gastroenteritis in Italy (coverage rate 90%) Payer Perspective Societal Perspective Direct Costs Direct + Indirect Costs Millions % Millions % No Rotavirus Vaccination 6 Rotavirus Vaccination No Rotavirus Vaccination 16 Rotavirus Vaccination Cost of RVGE disease Base-case scenario children Coverage rate = 90% 14
15 Need to target a high coverage rate to ensure optimal reduction of RVGE burden 0% 90 % Coverage rate 80 % Coverage rate 70 % Coverage rate -20% Reduction in RVGE Burden -40% -60% -80% -80% -75% -70% -71% -67% -59% -62% -59% -52% -100% Highest case efficacy Base-case efficacy Minimum case efficacy 15
16 Impact of the Vaccine on the RVGE Burden in Italy - 59% Without program With program between the 2 Policies Deaths Hospitalisations Nosocomial infections Emergency visits Physician visits Cases treated at home Base-case scenario Birth cohort : children Coverage rate = 70% 16
17 Main Limitations of the Model A few assumptions required experts opinions Impact on families not included No assessment of Quality of Life The price of the vaccine may differ in European countries, according also to the vaccination policy adopted. A model considering different scenarios including different prices, coverage etc is being developed. 17
18 Conclusions High Burden of RVGE in Italy: More than cases Total cost = 75 Millions Positive Impact of Pentavalent Rotavirus Vaccine: With a 70-90% coverage rate vaccination would reduce the burden of RVGE by %: hospitalisations emergency visits physician visits, - considerable work days lost. 18
19 Acknowledgements All PIs: C. Giaquinto J. Paricio L. Gothefors P. Todd F. Huet M. Tomàs C. Hülße P. Van Damme All FPs Cenbiotech & Sanofi-Pasteur MSD Teams And all the children and families 19
20 BACK-UP SLIDES 20
21 Model Inputs Pentavalent Rotavirus Vaccine Efficacy / Effectiveness GP cases Emergency cases Hospitalisations Nosocomial infections Deaths Cases not seeking care Efficacy for children receiving at least 1 dose Waning rate Coverage rate * Base-case efficacy ** [Minimum efficacy, Highest efficacy] Efficacy % * [95%CI: 73.9 % %] ** % * [95%CI: 88.8 % %] ** % * [95%CI: 90.5 % %] ** % * [95%CI: 90.5 % %] ** % * [95%CI: 90.5 % %] ** % * [95%CI: 73.9 % %] ** 60 % * 10 % after 2 years * 90 % * [70 % - 80 %] ** Source / Justification Vesikari et al. New Engl J Med (2006) Assumption: same as hospitalised cases Assumption: same as hospitalised cases Assumption: same as GP cases Vesikari et al. New Engl J Med (2006) Assumption: based on REST data Estimations of coverage rates for infants 21
22 Main Economic Inputs - Italy Payer Society Source / Justification Nosocomial infections Extra length of stay: 1.7 day Gianino et al. JHI (2002) Soriano et al. PIJD (2006) Cases treated at home work day lost for working mothers (55%) (OECD indicators), Eurostat (2002) 22
23 Huge Impact of the Vaccine on the RVGE Burden in Italy - 75% Without program With program between the 2 Policies Deaths Hospitalisations Nosocomial infections Emergency visits Physician visits Cases treated at home Base-case scenario Birth cohort : children Coverage rate = 90% 23
24 Huge Impact of the Vaccine on the RVGE Burden in Italy - 67% Without program With program between the 2 Policies Deaths Hospitalisations Nosocomial infections Emergency visits Physician visits Cases treated at home Base-case scenario Birth cohort : children Coverage rate = 80% 24
Effectiveness of rotavirus vaccination Generic study protocol for retrospective case control studies based on computerised databases
TECHNICAL DOCUMENT Effectiveness of rotavirus vaccination Generic study protocol for retrospective case control studies based on computerised databases www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT Effectiveness
More informationPrevention of Rotavirus Infections. Dr. ANCA DRAGANESCU INBI Matei Bals Bucuresti
Prevention of Rotavirus Infections Dr. ANCA DRAGANESCU INBI Matei Bals Bucuresti Worldwide, Rotavirus Accounted for ~215,000 Childhood Deaths Annually 1 (2000-2013) In children less than 5 years of age:
More informationSetting The setting was community. The economic study was carried out in the USA.
Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children Lieu T A, Ray G T, Black S R, Butler J C, Klein J O, Breiman R F, Miller M A, Shinefield H R Record
More informationValue of post-licensure data to assess public health value Example of rotavirus vaccines
Value of post-licensure data to assess public health value Example of rotavirus vaccines TM Umesh D. Parashar Lead, Viral Gastroenteritis Team CDC, Atlanta, USA uparashar@cdc.gov 1 Two New Rotavirus Vaccines
More informationSetting The setting was primary care. The economic study was carried out in Brazil, France, Germany and Italy.
The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model Aballea S, Chancellor J, Martin M, Wutzler P, Carrat F, Gasparini R, Toniolo-Neto J, Drummond M, Weinstein
More informationAssessing public health impact through vaccine probe analyses. Robert F. Breiman Emory Global Health Institute Emory University
Assessing public health impact through vaccine probe analyses Robert F. Breiman Emory Global Health Institute Emory University State of understanding the relative role of pathogens in major disease syndromes
More informationHow to measure impact of rotavirus vaccination: Opportunities for synergies across Nordic countries?
How to measure impact of rotavirus vaccination: Opportunities for synergies across Nordic countries? Elmira Flem Department of Vaccines Norwegian Institute of Public Health Nordic Vaccine Meeting April
More informationCorrelates of efficacy for human rotavirus vaccines Value of anti-rotavirus immunoglobulin A antibody concentrations
Correlates of efficacy for human rotavirus vaccines Value of anti-rotavirus immunoglobulin A antibody concentrations Brigitte Cheuvart, Kathleen M. Neuzil, Duncan Steele, Nigel Cunliffe, Shabir A. Madhi,
More informationThe Pentavalent Rotavirus Vaccine, RotaTeq : From Development to Licensure and Beyond
The Pentavalent Rotavirus Vaccine, RotaTeq : From Development to Licensure and Beyond Max Ciarlet, PhD Vaccines Clinical Research Department Merck Research Laboratories North Wales, Pennsylvania, United
More informationGSK Medicine: Rotarix (HRV): GlaxoSmithKline Biologicals live attenuated human rotavirus vaccine Study No.: (EPI-ROTA ) Title:
GSK Medicine: Rotarix (HRV): GlaxoSmithKline Biologicals live attenuated human rotavirus Study No.: 111426 (EPI-ROTA-111426) Title: Case-control study to evaluate the effectiveness of GlaxoSmithKline (GSK)
More informationA Human Rotavirus Vaccine
7th International Rotavirus Symposium Lisbon, Portugal, 12-13 June 2006 A Human Rotavirus Vaccine Dr. Béatrice De Vos GlaxoSmithKline Biologicals Rixensart, Belgium Rotarix is a trade mark of the GlaxoSmithKline
More informationCost effectiveness of pertussis vaccination in adults Lee G M, Murphy T V, Lett S, Cortese M M, Kretsinger K, Schauer S, Lieu T A
Cost effectiveness of pertussis vaccination in adults Lee G M, Murphy T V, Lett S, Cortese M M, Kretsinger K, Schauer S, Lieu T A Record Status This is a critical abstract of an economic evaluation that
More informationRotarix : Global Efficacy against Severe RV GE due to G1 and non-g1 (G2, G3, G4, G9) RV Types
Rotarix : Global Efficacy against Severe RV GE due to G1 and non-g1 (G2, G3, G4, G9) RV Types 8 th International Rotavirus Symposium Istanbul, 3 rd June 2008 Dr. Norman Begg, Vice President, Clinical Development
More informationCost effectiveness analysis of the new pneumococcal conjugate vaccine (Synflorix TM ) compared to Prevnar
CPHA 2009 Cost effectiveness analysis of the new pneumococcal conjugate vaccine (Synflorix TM ) compared to Prevnar Ismaila AS 1,2, Pereira JA 1, Robson RC 1, Rawson NS 1, Simpson SD 1, Standaert BA 3
More informationEfficacy of the pentavalent rotavirus vaccine, RotaTeq, in Finnish infants up to 3 years of age: the Finnish Extension Study
Eur J Pediatr (2010) 169:1379 1386 DOI 10.1007/s00431-010-1242-3 ORIGINAL PAPER Efficacy of the pentavalent rotavirus vaccine, RotaTeq, in Finnish infants up to 3 years of age: the Finnish Extension Study
More informationEconomic evaluation of Haemophilus influenzae type b vaccination in Slovenia Pokorn M, Kopac S, Neubauer D, Cizman M
Economic evaluation of Haemophilus influenzae type b vaccination in Slovenia Pokorn M, Kopac S, Neubauer D, Cizman M Record Status This is a critical abstract of an economic evaluation that meets the criteria
More informationUNIVAC decision support model A universal framework for evaluating vaccine policy options in low- and middle-income countries
UNIVAC decision support model A universal framework for evaluating vaccine policy options in low- and middle-income countries Andrew Clark, London School of Hygiene and Tropical Medicine Key questions
More informationEstimates of the economic burden of rotavirus-associated and all-cause diarrhoea in Vellore, India
Tropical Medicine and International Health doi:10.1111/j.1365-3156.2008.02094.x volume 13 no 7 pp 934 942 july 2008 Estimates of the economic burden of rotavirus-associated and all-cause diarrhoea in Vellore,
More informationPediatric Infectious Diseasess Society of the Philippines Journal Vol 15 No. 1 pp January June 2014
Pediatric Infectious Diseasess Society of the Philippines Journal ORIGINAL ARTICLE I-Heng Lee 1, Baudouin Standaert 2, Maria Carmen Nievera, MD 3, Jossie Rogacion, MD 4 1 Glaxo SmithKline Vaccines, Singapore,
More informationEffectiveness of monovalent rotavirus vaccine in the Philippines 13 th Rotavirus Symposium, 29 Aug 2018, Minsk, Belarus
Effectiveness of monovalent rotavirus vaccine in the Philippines 13 th Rotavirus Symposium, 29 Aug 2018, Minsk, Belarus Anna Lena Lopez, MD, MPH Director, Institute of Child Health and Human Development,
More informationPotential Health and Economic Impact of new Pneumococcal Vaccines Against Acute Otitis Media in Canada
CPHA 2010 Potential Health and Economic Impact of new Pneumococcal Vaccines Against Acute Otitis Media in Canada Afisi S. Ismaila a,b, Jennifer A. Pereira c, Reid C. Robson a, Gerhart Knerer d a Medical
More informationCost-effectiveness of a pediatric dengue vaccine Shepard D S, Suaya J A, Halstead S B, Nathan M B, Gubler D J, Mahoney R T, Wang D N, Meltzer M I
Cost-effectiveness of a pediatric dengue vaccine Shepard D S, Suaya J A, Halstead S B, Nathan M B, Gubler D J, Mahoney R T, Wang D N, Meltzer M I Record Status This is a critical abstract of an economic
More informationRotavirus vaccines: Issues not fully addressed in efficacy trials
Rotavirus vaccines: Issues not fully addressed in efficacy trials TM Umesh D. Parashar Lead, Viral Gastroenteritis Team CDC, Atlanta, USA uparashar@cdc.gov 1 Two New Rotavirus Vaccines Licensed in 2006
More informationPertussis in adolescents and adults: should we vaccinate Lee G M, LeBaron C, Murphy T V, Lett S, Schauer S, Lieu T A
Pertussis in adolescents and adults: should we vaccinate Lee G M, LeBaron C, Murphy T V, Lett S, Schauer S, Lieu T A Record Status This is a critical abstract of an economic evaluation that meets the criteria
More informationVaccines against Rotavirus & Norovirus. Umesh D. Parashar CDC, Atlanta, GA
TM Vaccines against Rotavirus & Norovirus Umesh D. Parashar CDC, Atlanta, GA 1 Rotavirus is the Leading Cause Of Severe Diarrhea in Children
More informationthe use of a combination of diphtheria, tetanus, and whole-cell pertussis vaccine (DTwP); and
Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997 Ekwueme D U, Strebel P M, Hadler S
More informationREVIEW ARTICLE The paediatric burden of rotavirus disease in Europe
Epidemiol. Infect. (2006), 134, 908 916. f 2006 Cambridge University Press doi:10.1017/s0950268806006091 Printed in the United Kingdom REVIEW ARTICLE The paediatric burden of rotavirus disease in Europe
More informationViral Agents of Paediatric Gastroenteritis
Viral Agents of Paediatric Gastroenteritis Dr Carl Kirkwood -------------------- Enteric Virus Research Group Murdoch Childrens Research Institute Royal Children s Hospital Victoria. WHO Collaborating
More informationHPV, Cancer and the Vaccination Programme
HPV, Cancer and the Vaccination Programme Dr Brenda Corcoran Consultant in Public Health Medicine HSE National Immunisation Office What is HPV? Human papillomavirus Over 200 types identified Spread by
More informationThe cost-effectiveness of expanded testing for primary HIV infection Coco A
The cost-effectiveness of expanded testing for primary HIV infection Coco A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract
More informationGSK VACCINES: KEY GROWTH DRIVERS
GSK VACCINES: KEY GROWTH DRIVERS Martin Andrews Senior Vice President, Global Vaccines Centre of Excellence, GSK Biologicals Millions of children die from infectious diseases Many of these deaths are preventable
More informationUpdate on Pentavalent Human-Bovine Rotavirus Vaccine. Michelle Goveia, MD, MPH Medical Director MSD Vaccines India, September 2014
Update on Pentavalent Human-Bovine Rotavirus Vaccine Michelle Goveia, MD, MPH Medical Director MSD Vaccines India, September 2014 Outline Characteristics of RotaTeq and its worldwide use Recent data evaluating
More informationCost-effectiveness of influenza vaccination in high-risk children in Argentina Dayan G H, Nguyen V H, Debbag R, Gomez R, Wood S C
Cost-effectiveness of influenza vaccination in high-risk children in Argentina Dayan G H, Nguyen V H, Debbag R, Gomez R, Wood S C Record Status This is a critical abstract of an economic evaluation that
More informationHealth technology Four strategies for the control of serogroup C meningococcal disease (CMD) were examined. These were:
Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease De Wals P, Nguyen V H, Erickson L J, Guay M, Drapeau J, St-Laurent J Record Status This is a critical
More informationSamir K Saha, Ph.D Child Health Research Foundation Dhaka Shishu Hospital Dhaka, Bangladesh
Barriers Rotavirus to Rotavirus Vaccine Impact Vaccine Beyond Preventing Introduction Diarrhea Samir K Saha, Ph.D Child Health Research Foundation Dhaka Shishu Hospital Dhaka, Bangladesh 13 th International
More informationDr. Bernd Benninghoff GSK Vaccines, GML Global Medical Affairs Director
ROTARIX the human rotavirus vaccine: -is applied in a 2-dose schedulecompletes the course at the earliest possible age, prevents morbidity and mortality from RV GE regardless of the circulating strains
More informationDownloaded from:
Yamin, D; Atkins, KE; Remy, V; Galvani, AP (2016) Cost-Effectiveness of Rotavirus Vaccination in France-Accounting for Indirect Protection. Value in health, 19 (6). pp. 811-819. ISSN 1098-3015 DOI: https://doi.org/10.1016/j.jval.2016.05.011
More informationCost-effectiveness of routine immunization to control Japanese encephalitis in Shanghai, China Ding D, Kilgore P E, Clemens J D, Liu W, Xu Z Y
Cost-effectiveness of routine immunization to control Japanese encephalitis in Shanghai, China Ding D, Kilgore P E, Clemens J D, Liu W, Xu Z Y Record Status This is a critical abstract of an economic evaluation
More informationRotavirus serotype surveillance: Results and experiences in Tanzania. Adolfine Hokororo. KPA Vaccinology Symposium- 29 th April
Rotavirus serotype surveillance: Results and experiences in Tanzania Adolfine Hokororo KPA Vaccinology Symposium- 29 th April 2016 1 outline 1. Introduction-burden of RVGE 2. goals of RVGE sentinel surveillance
More informationGlobal and National Trends in Vaccine Preventable Diseases. Dr Brenda Corcoran National Immunisation Office.
Global and National Trends in Vaccine Preventable Diseases Dr Brenda Corcoran National Immunisation Office Global mortality 2008 Children under 5 years of age 1.5 million deaths due to vaccine preventable
More informationUK (Scotland) childhood influenza vaccination programme experience from seasons 2013/14 and 2014/15
UK (Scotland) childhood influenza vaccination programme experience from seasons 2013/14 and 2014/15 Dr Beatrix v. Wissmann Epidemiologist Respiratory Viral Team Health Protection Scotland Overview Scotland:
More informationGSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/ Centres: Research Methods: Data Source Study Design
GSK Medicine: Rotarix (HRV1): GlaxoSmithKline (GSK) Biologicals oral live attenuated human rotavirus vaccine Study No.: 114910 (EPI-ROTA-025 VE AU DB) Title: A study on the impact of rotavirus vaccination
More informationEconomic Evaluation of a Universal Childhood Pneumococcal Conjugate Vaccination Strategy in Ireland
Volume 11 Number 5 2008 VALUE IN HEALTH Economic Evaluation of a Universal Childhood Pneumococcal Conjugate Vaccination Strategy in Ireland Lesley Tilson, BSc (Pharm), PhD, 1 Cara Usher, BSc, PhD, 1 Karina
More informationCritical immunity thresholds for measles elimination
Critical immunity thresholds for measles elimination Sebastian Funk Centre for the Mathematical Modelling of Infectious Diseases London School of Hygiene & Tropical Medicine 19 October, 2017!"vöå"!(}å!öZ&!
More informationEUROPID Presentation
EUROPID Presentation A presentation to give an overall view of PIDs in Europe. This has been presented at the EU Parliament and can be translated for use in support of national requests for funding PID
More informationCrucial factors that influence cost-effectiveness of universal hepatitis B immunization in India Prakash C
Crucial factors that influence cost-effectiveness of universal hepatitis B immunization in India Prakash C Record Status This is a critical abstract of an economic evaluation that meets the criteria for
More informationPharmacoeconomic Spotlight on Rotavirus Vaccine RIX4414 (RotarixÔ) in Developed Countries y
ADIS SPOTLIGHT Drugs R D 2012; 12 (4): 239-244 1179-6901/12/0004-0239 Adis ª 2012 Springer International Publishing AG. This is an open access article published under the terms of the Creative Commons
More informationGSK Medicine: Study No.: Title: Rationale: Study Period Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSetting The setting was primary care. The economic study was carried out in Norway.
Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program Wisloff T, Abrahamsen T G, Bergsaker M A, Lovoll O, Moller P, Pedersen M K, Kristiansen
More informationSAGE deliberations on CYD-TDV ( Dengvaxia )
SAGE deliberations on CYD-TDV ( Dengvaxia ) Annelies Wilder-Smith Consultant, Vaccines for Arboviral Diseases, WHO-IVB Scientific Coordinator ZIkaPLAN Director, Partnership for Dengue Control, Fondation
More informationEconomic Evaluation. Defining the Scope of a Costeffectiveness
Economic Evaluation Defining the Scope of a Costeffectiveness Analysis II This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes
More informationStudy population Patients in the UK, with moderate and severe depression, and within the age range 18 to 93 years.
Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK Borghi J, Guest J F Record Status This is a critical abstract
More informationAssessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model
Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model Aggarwal R, Ghoshal U C, Naik S R Record Status This is
More informationRotavirus: WHO Global Recommendations, Policy, and Surveillance
Rotavirus: WHO Global Recommendations, Policy, and Surveillance 9 th International Rotavirus Symposium 2 August 2010 Mary Agócs, MD, MSc Department of Immunization, Vaccines & Biologicals From 1999 2009:
More informationPopulation effectiveness of the pentavalent and monovalent rotavirus vaccines: a systematic review and meta-analysis of observational studies
Hungerford et al BMC Infectious Diseases (2017) 17:569 DOI 101186/s12879-017-2613-4 RESEARCH ARTICLE Population effectiveness of the pentavalent and monovalent rotavirus vaccines: a systematic review and
More informationUpdate on H1N1 vaccine immunogenicity, safety and effectiveness
Update on H1N1 vaccine immunogenicity, safety and effectiveness Dr David J Wood QSS/IVB/WHO SAGE 14 Apr 10 Immunogenicity outcomes (SAGE Oct 2009) Both adjuvanted and non-adjuvanted inactivated influenza
More informationCost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults Hornberger J, Robertus K
Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults Hornberger J, Robertus K Record Status This is a critical abstract of an economic evaluation that meets
More informationTraining in Infectious Diseases Modeling. A reflection on vaccination as a disease control measure
Training in Infectious Diseases Modeling A reflection on vaccination as a disease control measure -Example of Rotavirus disease- Participant s Guide Adapted by Nathalie Elomeiri; Camelia Savulescu; Fernando
More informationCost-Effectiveness of Rotavirus Vaccination for Under-Five Children in Iran
Iran J Pediatr. 2015 August; 25(4):e2766. Published online 2015 August 24. DOI: 10.5812/ijp.2766 Research Article Cost-Effectiveness of Rotavirus Vaccination for Under-Five Children in Iran Sareh Shakerian
More informationCost-effectiveness of Influenza Vaccine
Cost-effectiveness of Influenza Vaccine Lisa A. Prosser, PhD, MS Associate Professor University of Michigan National Influenza Vaccine Summit May 16, 2012 Acknowledgments Funding for this research project
More informationSource of effectiveness data The effectiveness data were derived from a review of completed studies and authors' assumptions.
Cost-effectiveness of hepatitis A-B vaccine versus hepatitis B vaccine for healthcare and public safety workers in the western United States Jacobs R J, Gibson G A, Meyerhoff A S Record Status This is
More informationAssessing the Evidence for Potential Benefits and Risks of Removing the Age Restrictions for Rotavirus Vaccination
Assessing the Evidence for Potential Benefits and Risks of Removing the Age Restrictions for Rotavirus Vaccination Manish Patel SAGE Geneva 12 April 2012 1 Overview! Update new inputs for benefit risk
More informationMethodologies for vaccine safety surveillance. Nick Andrews, Statistics Unit Public Health England October 2015
Methodologies for vaccine safety surveillance Nick Andrews, Statistics Unit Public Health England October 2015 Some dramas of the past 20 years which do you think turned out to be real adverse reactions?
More informationThe economic impact of quarantine: SARS in Toronto as a case study Gupta A G, Moyer C A, Stern D T
The economic impact of quarantine: SARS in Toronto as a case study Gupta A G, Moyer C A, Stern D T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion
More informationCost of Disorders of the Brain in Europe Gustavsson et al. Cost of disorders of the brain in Europe Eur. Neuropsych. (2011) 21,
Cost of Disorders of the Brain in Europe 2010 Gustavsson et al. Cost of disorders of the brain in Europe 2010. Eur. Neuropsych. (2011) 21, 718-779 Steering Committee Prof Jes Olesen 1 Prof Bengt Jönsson
More informationHousehold transmission of rotavirus in Malawian children with acute gastroenteritis is associated with disease severity
Household transmission of rotavirus in Malawian children with acute gastroenteritis is associated with disease severity Dr Aisleen Bennett International Rotavirus Symposium, Minsk, Belarus August 2018
More informationCore 3: Epidemiology and Risk Analysis
Core 3: Epidemiology and Risk Analysis Aron J. Hall, DVM, MSPH, DACVPM CDC Viral Gastroenteritis Team NoroCORE Full Collaborative Meeting, Atlanta, GA November 7, 2012 Core 3: Purpose and Personnel * Purpose:
More informationVaccine 27 (2009) Contents lists available at ScienceDirect. Vaccine. journal homepage:
Vaccine 27 (2009) 4891 4904 Contents lists available at ScienceDirect Vaccine journal homepage: www.elsevier.com/locate/vaccine Review Cost-effectiveness of pneumococcal polysaccharide vaccination in adults:
More informationEconomic evaluation of tandem mass spectrometry screening in California Feuchtbaum L, Cunningham G
Economic evaluation of tandem mass spectrometry screening in California Feuchtbaum L, Cunningham G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion
More informationUNDERSTANDING ATOPIC DERMATITIS IN ITALY
UNDERSTANDING ATOPIC DERMATITIS IN Key points: Around 17% of people in Italy would have atopic dermatitis (AD) at some point in their life known as lifetime prevalence ; the disease is highly prevalent
More informationViral Hepatitis Prevention Board
Viral Hepatitis Prevention Board Hepatitis B vaccination: A completed schedule Enough to control HBV lifelong? Milan, Italy November 17-18, 2011 The Viral Hepatitis Prevention Board 19 years of support
More informationCost-Effectiveness of Quadrivalent vs Monovalent Vaccination against Meningococcal Disease in Canada
Cost-Effectiveness of Quadrivalent vs Monovalent Vaccination against Meningococcal Disease in Canada Derek Weycker, Ph.D. 1 Mark Atwood, M.S. 1 Thomas E. Delea, M.S.I.A. 1 Anoush Youssoufian, B.A. 1 Dion
More informationThe cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden Bolin K, Lindgren B, Willers S
The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden Bolin K, Lindgren B, Willers S Record Status This is a critical abstract of an economic evaluation
More informationBangladesh: How to move from data to implementation. K. Zaman, MBBS, PhD Senior Scientist and Epidemiologist icddr,b
Bangladesh: How to move from data to implementation K. Zaman, MBBS, PhD Senior Scientist and Epidemiologist icddr,b Rotavirus in Bangladesh Estimated 2.4 million cases of rotavirus diarrhoea annually in
More informationHepatitis B vaccine alone or with HBIG in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis.
Hepatitis B vaccine alone or with HBIG in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis. Vana Papaevangelou (Greece) National and Kapodistrian University of Athens Chang SemFNM
More informationBudget Impact and Cost-Effectiveness of Including a Pentavalent Rotavirus Vaccine in the New Zealand Childhood Immunization Schedulevhe_
Volume 12 Number 6 2009 VALUE IN HEALTH Budget Impact and Cost-Effectiveness of Including a Pentavalent Rotavirus Vaccine in the New Zealand Childhood Immunization Schedulevhe_534 888..898 Richard J. Milne,
More informationSAGE Working Group on Pertussis Vaccines. Summary of Evidence: Resurgence Potential and Vaccine Impacts
SAGE Working Group on Pertussis Vaccines Summary of Evidence: Resurgence Potential and Vaccine Impacts E. Miller, SAGE Pertussis Working Group Member and Chair until February 2014 WHO SAGE Meeting April
More informationCOMMISSION OF THE EUROPEAN COMMUNITIES
COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 22.12.2008 COM(2008) 882 final REPORT FROM THE COMMISSION TO THE COUNCIL, THE EUROPEAN PARLIAMENT, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE
More informationBack to Basics: Regional Progress Towards Measles and Rubella Elimination and Introduction of New Vaccines WHO European Regional Office
Back to Basics: Regional Progress Towards Measles and Rubella Elimination and Introduction of New Vaccines WHO European Regional Office SAGE, Geneva 27 October 2009 Rebecca Martin Targeted Diseases and
More informationMeasles and rubella monitoring January 2015
Measles and rubella monitoring January 215 Reporting on January December 214 surveillance data and epidemic intelligence data to the end of January 215 Main developments Measles During the 12-month period
More informationHEPATITIS C ELIMINATION IN GREECE
HEPATITIS C ELIMINATION IN GREECE ANGELOS HATZAKIS Professor of Epidemiology & Preventive Medicine Athens University Medical School Co-Chair, Hepatitis B & C Public Policy Association London, UK June 5,
More informationHepatitis B vaccination worldwide: Lessons learnt and the way forward
Hepatitis B vaccination worldwide: Lessons learnt and the way forward VHPB Russia meeting Oct 2018 Pierre Van Damme MD, PhD History Hepatitis B vaccines have been available since early 1980 s First recommended
More informationShabir A. Madhi. Progress and Challenges of Immunization Contributing Toward Attaining the MDG Goal to Reduce under-5 Childhood Mortality.
Shabir A. Madhi Progress and Challenges of Immunization Contributing Toward Attaining the MDG Goal to Reduce under-5 Childhood Mortality. National Institute for Communicable Diseases & University of Witwatersrand,
More informationClopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Schleinitz M D, Weiss J P, Owens D K
Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Schleinitz M D, Weiss J P, Owens D K Record Status This is a critical abstract of an economic evaluation
More informationHealth technology Four treatments for patients with persistent symptoms of asthma were examined:
Adding formoterol to budesonide in moderate asthma: health economic results from the FACET study Andersson F, Stahl E, Barnes P J, Lofdahl C G, O'Byrne P M, Pauwels R A, Postma D S, Tattersfield A E, Ullman
More informationImproving Type-2 Diabetes Therapy Adherence and Persistence in Turkey
November 2017 Improving Type-2 Diabetes Therapy Adherence and Persistence in Turkey How to Address Avoidable Economic and Societal Burden PATIENT ACTIVATION Introduction This Appendix document provides
More informationDirector of Public Health Board Paper No. 13/13
Greater Glasgow and Clyde NHS Board Director of Public Health Board Paper No. 13/13 Report of the Director of Public Health : Major Development to Immunisation Programmes in Scotland Implications for NHSGGC
More informationDecision-making by the Advisory Committee on Immunization Practices
Decision-making by the Advisory Committee on Immunization Practices Melinda Wharton, MD, MPH Deputy Director, National Center for Immunization & Respiratory Diseases Institute of Medicine 9 February 2012
More informationSetting The setting was secondary care. The economic study was carried out in France.
Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France Omnes L F, Bousquet J, Scheinmann P, Neukirch F, Jasso-Mosqueda G,
More informationDeployment of Combination Vaccines and STI vaccines
Deployment of Combination Vaccines and STI vaccines Advancing Prevention Technologies for Sexual and Reproductive Health Symposium Berkeley, Ca March 24, 2009 Eileen Yamada, MD, MPH California Department
More information2008 Landes Bioscience. Do not distribute.
[Human Vaccines 5:3, 1-5; March 2009]; 2009 Landes Bioscience This manuscript has been published online, prior to printing.once the issue is complete and page numbers have been assigned, the citation will
More informationNeonatal hearing screening: modelling cost and effectiveness of hospital- and communitybased
Neonatal hearing screening: modelling cost and effectiveness of hospital- and communitybased screening Grill E, Uus K, Hessel F, Davies L, Taylor R S, Wasem J, Bamford J Record Status This is a critical
More informationHexavalent Vaccines: Hepatitis B antibody response and co-administration with other vaccines
Viral Hepatitis Prevention Board Hanoi, 25 26 July 2018 Hexavalent Vaccines: Hepatitis B antibody response and co-administration with other vaccines Prof. Timo Vesikari Vaccine Research Center University
More informationPneumococcal vaccination in UK: an update. Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections
Pneumococcal vaccination in UK: an update Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections Leading infectious causes of mortality, 2000 WHO estimates 3.5 Deaths
More informationSTRATEGIC PLAN AGAINST VIRAL HEPATITIS IN SENEGAL ( ) POLICY BRIEF
PROGRAMME NATIONAL DE LUTTE CONTRE LES HEPATITES STRATEGIC PLAN AGAINST VIRAL HEPATITIS IN SENEGAL (2019-2023) POLICY BRIEF 1 INVESTING IN THE FIGHT AGAINST HEPATITIS B AND C IN SENEGAL NATIONAL STRATEGIC
More informationSetting The setting was secondary care. The economic study was carried out in Sweden.
Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study Borgstrom F, Johnell O, Kanis J A, Oden A, Sykes D, Jonsson B Record Status This
More information